Skip to main content
. 2014 Mar 24;105(4):481–489. doi: 10.1111/cas.12378

Table 4.

Frequent regions of genomic imbalances in each subgroup of germinal center B-cell-like (GCB) or non-GCB diffuse large B-cell lymphoma (DLBCL) identified by immunostaining

(a) Frequent regions of genomic gains in each sub group of GCB DLBCL identified by immunostaining
GCB gain
CD10+ only
BCL6+ only
CD10+BCL6+
CD10+BCL6+MUM1+
Chromosome band % (n/CD10+only) Chromosome band % (n/BCL6+ only) Chromosome band % (n/CD10+BCL6+) Chromosome band % (n/CD10+BCL6+MUM1+)
7q34–7q35 75 (6/8) 7q22.1, 7q22–7q31.1 83 (5/6) 2p16.2 80 (4/5) 1q21–1q25, 1q31–1q32, 1q41–1q44 100 (1/1)
11q23.3 75 (6/8) 2p14 67 (4/6) 7q22–7q31.1 80 (4/5) 2p12–2p16 100 (1/1)
1q23.3 63 (5/8) 3q29 67 (4/6) 11p11.2, 11q13.4, 11q22.1, 11q22.3, 80 (4/5) 3q13.2 100 (1/1)
2p16.1 63 (5/8) 7p11–7p14, 7q21–7q31 67 (4/6) 17q21.2, 17q24.1, 80 (4/5) 6p25.3 100 (1/1)
3q28 63 (5/8) 8q24.1 67 (4/6) 1q23.3, 1q25.1 60 (3/5) 6p21–6p25 100 (1/1)
7q22.1, 7q22–7q31.1, 7q31.1 – 7q34 63 (5/8) 12q13.12 67 (4/6) 2p16.1, 60 (3/5) 7p21–7p22 100 (1/1)
11q23.3, 11q23.3 63 (5/8) BCL2 67 (4/6) 3q23, 3q28 60 (3/5) 7p11–7p15, 7q11.23–7q21.1, 7q22–7q31, 7q36 100 (1/1)
6p21–6p23, 6q21 60 (3/5) 8q12–8q13, 8q21–8q24 100 (1/1)
7p22.1, 7p14–7p15, 7q31.2, 7q34 60 (3/5) 11p13 100 (1/1)
8q24.21 60 (3/5) 12q22, 12q24 100 (1/1)
11p13, 11q13– 11q14, 11q21–11q23 60 (3/5) 15q15.3 100 (1/1)
12q21, 12q24.31 60 (3/5) 17q12, 17q21.2, 17q25.3 100 (1/1)
14q23 60 (3/5) 18p11.32 100 (1/1)
15q23 60 (3/5) 20q12, 20q13.2 100 (1/1)
16p13.3 60 (3/5) 22q 100 (1/1)
17q25.3 60 (3/5)
(b) Frequent regions of genomic losses in each subgroup of GCB DLBCL identified by immunostaining
GCB loss
CD10+ only
BCL6+ only
CD10+BCL6+
CD10+BCL6+MUM1+
Chromosome band % (n/CD10+ only) Chromosome band % (n/BCL6+ only) Chromosome band % (n/CD10+BCL6+) Chromosome band % (n/CD10+BCL6+MUM1+)
10q25.1 50 (4/8) 4p15.31 83 (5/6) 16q12, 16q22– 16q24 60 (3/5) 1p36,1p35, 1p34.3 100 (1/1)
6q16.3 50 (4/8) 6q22.33 67 (4/6) 18q12.2d 60 (3/5) 2q14.3, 2q35 100 (1/1)
9p21.3 50 (4/8) 1p36.32, 1p31.1, 1q43 67 (4/6) 1p36.13 60 (3/5) 3q27.2, 3q28, 3q29 100 (1/1)
16q12.2 50 (4/8) 3p12.1–p12.2 67 (4/6) 2p24 60 (3/5) 4q34.3 100 (1/1)
16q24 50 (4/8) 4q13.1 67 (4/6) 2q14.3, 2q21– 2q24 60 (3/5) 5p15.33 100 (1/1)
6q23.2 67 (4/6) 5p15.33 60 (3/5) 6q14–6q16, 6q21–6q27 100 (1/1)
8p22 67 (4/6) 6q26, 6q27 60 (3/5) 11q21, 11q22 100 (1/1)
16p13.2, 16q12, 16q23.3 67 (4/6) 8p21.3, 8q24.23 60 (3/5) 13q13.1–13q13.3, 13q14 100 (1/1)
16q12, 16q21 100 (1/1)
17q25.3 100 (1/1)
22q13 100 (1/1)
(c) Frequent regions of genomic gains in each subgroup of Non-GCB DLBCL identified by immunostaining
Non-GCB gain
MUM1+ only
BCL6+MUM1+
Chromosome band % (n/MUM1+only) Chromosome band % (n/BCL6+MUM1+)
1q31 69 (9/13) 3q13.2 64 (7/11)
1q24.2, 1q24.3, 1q25.1, 1q31.2, 1q31.3-q32.1 62 (8/13) 11q24.3 64 (7/11)
1q22, 1q23.3, 1q25.1, 1q25.3, 1q31.1, 1q31.2, 1q31.3, 1q32.1 54 (7/13) 3q12.3 55 (6/11)
3q29 54 (7/13) 3q23 55 (6/11)
7q22-7q31.1 54 (7/13) 7q22-7q31.1 55 (6/11)
9p24.2, 9p24.1, 9q34.3 54 (7/13) 11-075-1 55 (6/11)
11q24.1, 11q24.3, 54 (7/13) 11q24.3 55 (6/11)
12p11.21, 12q12, 12q15, 12q21.33, 12q22, 12q24.31 54 (7/13) 14q23.1c 55 (6/11)
18q21 54 (7/13)
(d) Frequent regions of genomic losses in each subgroup of Non-GCB DLBCL identified by immunostaining
Non-GCB loss
MUM1 only
BCL6+MUM1+
Chromosome band % (n/MUM1 only) Chromosome band % (n/BCL6+MUM1+)
14q32.13 54 (7/13) 6q16.3 64 (7/11)
1p36.32, 1p36.23-31, 1p36.13 54 (7/13) 6q12 55 (6/11)
2q21.1 54 (7/13) 6q23.2, 6q23.3, 6q24.2, 6q25.3, 6q13, 6q15, 6q16.1, 6q16.2, 6q22.31, 6q22.33, 45 (5/11)
8p21.3 54 (7/13) 2q14.3 45 (5/11)
9p21.3 46 (6/13) 8p21.3 45 (5/11)
14q24.3 46 (6/13) 16q12.2 45 (5/11)
5p15 46 (6/13)
5p15.32 46 (6/13)
15q12, 15q26.1 46 (6/13)
1p35.1, 1p34.3, 1q43 46 (6/13)
2q12.2, 2q14.1 46 (6/13)
6q21, 6q27 46 (6/13)
8p23, 8q24.23 46 (6/13)
10q22.3, 10q25.1 46 (6/13)
15q11.2 46 (6/13)
16q12.2 46 (6/13)
16q23.3 46 (6/13)
20q13.33 46 (6/13)

Tables 4a–d: Copy number change of X chromosome was excluded. n, case numbers in each subgroup of GCB or non-GCB DLBCL identified by immunostaining. %, percentage of positive cases in each subgroup of GCB or non-GCB DLBCL identified by immunostaining.